Related Experiment Video
Updated: Sep 28, 2026

Trabeculotome Tunneling Trabeculoplasty (3T): A Step-by-Step Surgical Protocol for Primary Open-angle Glaucoma
Published on: May 29, 2026
The short-term IOP-lowering effect of brimonidine 0.2% and dorzolomide 2% combination in primary open-angle glaucoma
Sitki Samet Ermis1, Faruk Ozturk, Umit Ubeyt Inan
1Department of Opthalmology, School of Medicine, University of Afyon Kocatepe, Afyon, Turkey. sametermis@hotmail.com
Purpose:
To evaluate the ocular hypotensive effect of dorzolamide 2% in primary open-angle glaucoma (POAG) patients with intraocular pressure (IOP) of at least 22 mmHg despite ongoing twice daily treatment with brimonidine 0.2%.
Patients And Methods:
Nineteen eyes of 19 patients with POAG and IOP >or= 22 mmHg, on twice daily brimonidine therapy, were included in the study. Intraocular pressure and adverse effects were recorded on days 2, 7, 14 and 30 after adding dorzolamide three times daily to the treatment.
Results:
Mean pretreatment IOP was 27.6 +/- 2.2 mmHg. This decreased to 24.2 +/- 2.2 mmHg after a mean duration of 23.8 +/- 12.1 days. After dorzolamide was added to the treatment, mean IOP was 20.8 +/- 2.3 mmHg on day 2, 19.3 +/- 2.2 mmHg on day 7, 18.0 +/- 2.5 mmHg on day 14 and 17.2 +/- 2.3 mmHg on day 30. The differences between pre- and post-treatment IOP values were statistically significant (p < 0.0001, anova test).
Conclusion:
Dorzolamide administered three times daily has significant additive ocular hypotensive effect in POAG patients whose IOP is elevated despite ongoing treatment with brimonidine.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Ophthalmic Drug Delivery Systems
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Direct-Acting Cholinergic Agonists: Pharmacological Actions